Multiple Sclerosis Disease (MS) is on a Mission to
Make Your Health, Wellness and Longevity a High Priority
About Multiple Sclerosis Disease (MS)
It's time to work on health and wellness, starting today with a more relaxed healthy lifestyle, exercise and healthy eating for your fitness and contributing to happiness, prosperity and longevity...
In the USA there are more than 500,000 people diagnosed with MS. Unfortunately, there's no pill type of easy and effective treatment for this chronic disease. But MS treatment and Meds may change soon because a promising oral medication is in the drug development pipeline, according to a recent study in The New England Journal of Medicine.
Although there are injectable treatments for those with MS, most MS drugs increase the risk of skin reactions and serious infections, so a pill-based form of medication is most welcome. An international group of researchers gave different doses of the experimental drug Fingolimod to 255 patients suffering from relapsing MS, a specific form of the disease most MS patients commence with.
Multiple Sclerosis (also known as MS) is considered an auto-immune disease in which the body's immune system attacks itself, attacking some protective tissues in the brain, and creates scar tissue. There are four types of MS: relapsing-remitting, primary-progressive, secondary-progressive and progressive-relapsing meningitis.
Recently, medical investigators tracked MS patients' progress over the course of the medical study with MRI scans and doctor evaluations. 6-months after the study began, the number of brain lesions; areas of the brain damaged by the disease; was lowered significantly in most patients, and the majority of the patients experienced a 50-percent drop in relapses.
So does the new MS drug work better than injections? Not necessarily. Many injectable drugs have advantages, including ability to reduce brain lesions and may reduce MS attacks by 30-percent to 60-percent or even more, according to clinical trials.
But Multiple Sclerosis is an unpredictable disease can change month-to-month or day-to-day, and Multiple Sclerosis drugs which may work for a patient one day may not stay working for the same patient after a while. So, MS researchers were pleased to find some patients who continued to take Fingolimod continued to respond well to he medication, even over a year after the multiple sclerosis MS study started.